CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely Via Induction of Hippo-Yap Signaling

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2019 Apr 3

PMID 30935014

Citations 42

Authors

Chih-Jen Lai

Ching-Yu Lin

Wen-Ying Liao

Tzyh-Chyuan Hour

Horng-Dar Wang

Chih-Pin Chuu

Affiliations

Soon will be listed here.

Abstract

Patients receiving docetaxel developed a drug resistance within a few months. We generated docetaxel-resistant PC/DX25 and DU/DX50 CRPC cells from PC-3 and DU-145 PCa cells, respectively. We investigated the mechanism behind why PC/DX25 and DU/DX50 cells exhibited higher migration and invasion ability. Transwell assays were used to measure the migration and invasion of PCa cell. Fluorescence activated cell sorter (FACS) analysis was used to determine the population of cancer stem cell (CSC)-like cell. Micro-Western Array (MWA) was used to study the changes of the protein profile. FACS analysis revealed that PC/DX25 cells and DU/DX50 cells contain higher CD44+ population. MWA and Western blotting assay revealed that protein expression of CD44, YAP, CYR61, CTGF, phospho-ERK1/2 T202/Y204, ERK and vimentin was elevated in PC/DX25 cells. Knockdown of CD44 or YAP suppressed migration and invasion of PC/DX25 and DU/DX50 cells. Knockdown of CD44 decreased expression of YAP, CTGF and CYR61 but increased phosphorylation of S127 on YAP. CD44 knockdown also suppressed protein level of AKT, phospho-AKT T308, phospho-ERK1/2 T202/Y204 and vimentin. CD44 promotes migration and invasion of docetaxel-resistant PCa cells probably via induction of Hippo-Yap signaling pathway and CD44/YAP pathway may be a therapeutic target for docetaxel-resistant PCa.

Citing Articles

Regulating chemoresistance and cancer stemness: the CDH17-YAP pathway in distinct cellular states of lung cancer CTC clusters.

Que Z, Qi D, Yang Y, Yao W, Liu J, Li Y Cell Mol Biol Lett. 2025; 30(1):23.

PMID: 39994505 PMC: 11849222. DOI: 10.1186/s11658-025-00696-9.

The Hippo Signaling Pathway Manipulates Cellular Senescence.

Miyajima C, Nagasaka M, Aoki H, Toriuchi K, Yamanaka S, Hashiguchi S Cells. 2025; 14(1.

PMID: 39791714 PMC: 11719916. DOI: 10.3390/cells14010013.

Pan-cancer analysis of the prognostic and immunological role of hippo-YAP signaling pathway.

Yang J, Yang C, Yang G, Wang R, Li J, Song Y Discov Oncol. 2024; 15(1):504.

PMID: 39333438 PMC: 11436565. DOI: 10.1007/s12672-024-01212-9.

Cancer-associated fibroblasts and prostate cancer stem cells: crosstalk mechanisms and implications for disease progression.

Chen H, Fang S, Zhu X, Liu H Front Cell Dev Biol. 2024; 12:1412337.

PMID: 39092186 PMC: 11291335. DOI: 10.3389/fcell.2024.1412337.

Key genes and molecular mechanisms related to Paclitaxel Resistance.

Alalawy A Cancer Cell Int. 2024; 24(1):244.

PMID: 39003454 PMC: 11245874. DOI: 10.1186/s12935-024-03415-0.

References

Hour T, Chung S, Kang W, Lin Y, Chuang S, Huang A . EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol. 2014; 89(4):591-605. DOI: 10.1007/s00204-014-1275-x. View

Hellerstedt B, Pienta K . The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002; 52(3):154-79. DOI: 10.3322/canjclin.52.3.154. View

Hao Y, Chun A, Cheung K, Rashidi B, Yang X . Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem. 2007; 283(9):5496-509. DOI: 10.1074/jbc.M709037200. View

Tseng J, Lin C, Su L, Fu H, Yang S, Chuu C . CAPE suppresses migration and invasion of prostate cancer cells via activation of non-canonical Wnt signaling. Oncotarget. 2016; 7(25):38010-38024. PMC: 5122368. DOI: 10.18632/oncotarget.9380. View

Bourguignon L, Peyrollier K, Xia W, Gilad E . Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008; 283(25):17635-51. PMC: 2427357. DOI: 10.1074/jbc.M800109200. View

Guo Y, Cui J, Ji Z, Cheng C, Zhang K, Zhang C . miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance. Oncogene. 2017; 36(45):6336-6347. DOI: 10.1038/onc.2017.240. View

Petrylak D, Tangen C, Hussain M, Lara Jr P, Jones J, Taplin M . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351(15):1513-20. DOI: 10.1056/NEJMoa041318. View

Brown R, Reinke L, Damerow M, Perez D, Chodosh L, Yang J . CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011; 121(3):1064-74. PMC: 3049398. DOI: 10.1172/JCI44540. View

Zhao B, Ye X, Yu J, Li L, Li W, Li S . TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008; 22(14):1962-71. PMC: 2492741. DOI: 10.1101/gad.1664408. View

10.

Ponta H, Sherman L, Herrlich P . CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003; 4(1):33-45. DOI: 10.1038/nrm1004. View

11.

Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y . Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis. Cancer Lett. 2016; 385:215-224. DOI: 10.1016/j.canlet.2016.10.020. View

12.

Ploussard G, Terry S, Maille P, Allory Y, Sirab N, Kheuang L . Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res. 2010; 70(22):9253-64. PMC: 3290526. DOI: 10.1158/0008-5472.CAN-10-1447. View

13.

Hurt E, Kawasaki B, Klarmann G, Thomas S, Farrar W . CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008; 98(4):756-65. PMC: 2259168. DOI: 10.1038/sj.bjc.6604242. View

14.

Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang D . Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res. 2007; 67(14):6796-805. DOI: 10.1158/0008-5472.CAN-07-0490. View

15.

Naor D, Wallach-Dayan S, Zahalka M, Sionov R . Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol. 2008; 18(4):260-7. DOI: 10.1016/j.semcancer.2008.03.015. View

16.

Hao J, Madigan M, Khatri A, Power C, Hung T, Beretov J . In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS One. 2012; 7(8):e40716. PMC: 3411712. DOI: 10.1371/journal.pone.0040716. View

17.

Harvey K, Tapon N . The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer. 2007; 7(3):182-91. DOI: 10.1038/nrc2070. View

18.

Singh N, Liu G, Chakrabarty S . Isolation and characterization of calcium sensing receptor null cells: a highly malignant and drug resistant phenotype of colon cancer. Int J Cancer. 2012; 132(9):1996-2005. DOI: 10.1002/ijc.27902. View

19.

Antonarakis E, Keizman D, Zhang Z, Gurel B, Lotan T, Hicks J . An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer. 2012; 118(24):6063-71. PMC: 3572534. DOI: 10.1002/cncr.27689. View

20.

Xu Y, Stamenkovic I, Yu Q . CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res. 2010; 70(6):2455-64. PMC: 2840073. DOI: 10.1158/0008-5472.CAN-09-2505. View